Vivo Capital Surplus Fund VIII, L.P.

10% OwnerAligos Therapeutics, Inc. (ALGS) · full profile →Form 4 · filed Oct 20, 2020
Net Buying
Open-Market Buys
$8.3M
Open-Market Sells
$0
Net Open-Market Flow
$8.3M
Transactions
14
8 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 20, 2020Conversion(C)524K2.4M
Oct 20, 2020Conversion(C)224K2.6M
Oct 20, 2020Buy(P)67K$15.00$1.0M430K
Oct 20, 2020Conversion(C)72K333K
Oct 20, 2020Conversion(C)31K364K
Oct 20, 2020Buy(P)483K$15.00$7.2M3.1M
Oct 20, 2020Conversion(C)1.9M1.9M
Oct 20, 2020Conversion(C)260K260K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 20, 2020Conversion(C)72K$00
Oct 20, 2020Conversion(C)31K$00
Oct 20, 2020Conversion(C)224K$00
Oct 20, 2020Conversion(C)524K$00
Oct 20, 2020Conversion(C)260K$00
Oct 20, 2020Conversion(C)1.9M$00

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001567619-20-018010) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about ALGS insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001567619-20-018010"
Ask your agent
Use Arkolith to summarize insider buying and selling at Aligos Therapeutics, Inc.
over the last 90 days and cite the filings.